Title:Formulation, Design, Optimization, and Characterization of Novel
Long-acting Injectable Dosage Form of Anti-psychotic Drug
Volume: 19
Issue: 6
Author(s): Niraj Patel*, Rakesh Patel and Abhay Dharamsi
Affiliation:
- Parul Institute of Pharmacy, Parul University, P.O. Limda, Ta. Waghodia, Vadodara, Gujarat, 391760, India
Keywords:
Brexpiprazole (BRX), anti-psychotic drug, long-acting injectable, microspheres, drug delivery systems, quasi-emulsion solvent.
Abstract:
Background: The current research aimed to create and analyze a new long-acting Brexpiprazole
(BRX) injectable for successful anti-psychotic drug therapy in order to decrease dosage
frequency and increase patient compliance. Systems for drug transport to particular body sites or
regulating release rates with accuracy are known as drug delivery systems (DDS). By affixing the
drug to a carrier particle like liposomes, nanoparticles, microspheres, etc., which modifies the drug's
absorption and release properties, using carrier technology, drugs may be delivered in an intelligent
manner.
Methods: Utilizing Resomer RG 502 H and RESOMER® RG 752 H extended-release Polymer, Using
a quasi-emulsion solvent diffusion, microspheres were made, and emulsification and solvent
evaporation process.
Results: The produced microspheres were assessed for stability tests, in vitro drug release, flow characteristics,
and drug entrapment efficiency. FTIR experiments were used to establish how well the
drug excipients worked together. The acarbose microspheres that were created had an 89.9 to 96.1
percent drug entrapment efficiency. The impact of factors like polymer content on medication release
was studied. The Stability study of the formulation was carried out under different conditions, and
data were established. Comparative pharmacokinetic studies between marketed oral formulation and
Brexpirazole microsphere test formulations in Wistar/SD Rats were carried out and concluded.
Conclusion: Brexpiprazole (BRX) novel long-acting injectable formulation, could be used effectively
for the treatment of mentally challenged anti-psychotic patients worldwide.